Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...
Investor's Business Daily on MSN19h
Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?The FDA is due to make an approval decision on injectable Keytruda by mid-September. The move could bolster downtrodden Merck stock.
Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.
A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...
Pharmaceutical segment revenues beat the Zacks Consensus Estimate of $13.9 billion. All sales growth numbers discussed below exclude Fx impact. Keytruda, the biggest product in Merck’s portfolio ...
A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers caused by the human papillomavirus and one of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback